To study the optimal scheduling of palbociclib in combination with fulvestrant with the aim of improving patient outcomes with this treatment combination, we used a cell cycle–explicit model of ER+ breast cancer response to these drugs, parameterized using in vitro drug synergy and cell-cycle data. Here, ESR1 is linked to breast carcinoma.